Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2024

09.01.2024 | Clinical trial

The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey

verfasst von: Ana-Alicia Beltran-Bless, Gail Larocque, Muriel Brackstone, Angel Arnaout, Jean-Michel Caudrelier, Denise Boone, Parvaneh Fallah, Terry Ng, Peter Cross, Nasser Alqahtani, John Hilton, Lisa Vandermeer, Gregory Pond, Mark Clemons

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Despite limited evidence supporting its effectiveness, most guidelines recommend long-term, routinely scheduled in-person surveillance of patients with early breast cancer (EBC). The COVID-19 pandemic led to increased use of virtual care. This survey evaluated patient perspectives on follow-up care.

Methods

Patients with EBC undergoing surveillance were surveyed about follow-up protocols, perceptions, and interest in clinical trials assessing different follow-up strategies.

Results

Of 402 approached patients 270 completed the survey (response rate 67%). Median age 62.5 years (range 25–86) and median time since breast cancer diagnosis was 3.8 years (range < 1–33 years). Most (n = 148/244, 60%) were followed by more than one provider. Routine follow-ups with breast examination were mostly conducted by medical/radiation oncologists every 6 months (n = 110/236, 46%) or annually (n = 106/236, 44%). Participants felt routine follow-up was useful to monitor for recurrence, manage side effects of cancer treatment and to provide support/reassurance. Most participants felt regular follow-up care would detect recurrent cancer earlier (n = 214/255, 96%) and increase survival (n = 218/249, 88%). The COVID-19 pandemic reduced the number of in-person visits for 54% of patients (n = 63/117). Patients were concerned this reduction of in-person visits would lead to later detection of both local (n = 29/63, 46%) and distant recurrences (n = 25/63, 40%). While many felt their medical and radiation oncologists were the most suited to provide follow-up care, 55% felt comfortable having their primary care provider (PCP) conduct surveillance. When presented with a scenario where follow-up has no effect on earlier detection or survival, 70% of patients still wanted routine in-person follow-up for reassurance (63%) with the goal of earlier recurrence detection (56%).

Conclusions

Despite limited evidence of effectiveness of routine in-person assessment, patients continue to place importance on regularly scheduled in-person follow-up.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
7.
Zurück zum Zitat de Bock GH, Bonnema J, van der Hage J et al (2004) Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive Breast cancer: a meta-analysis and systematic review. J Clin Oncol off J Am Soc Clin Oncol 22:4010–4018. https://doi.org/10.1200/JCO.2004.06.080CrossRef de Bock GH, Bonnema J, van der Hage J et al (2004) Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive Breast cancer: a meta-analysis and systematic review. J Clin Oncol off J Am Soc Clin Oncol 22:4010–4018. https://​doi.​org/​10.​1200/​JCO.​2004.​06.​080CrossRef
8.
Zurück zum Zitat Schapira DV, Urban N (1991) A minimalist policy for Breast cancer surveillance. JAMA 265:380–382CrossRefPubMed Schapira DV, Urban N (1991) A minimalist policy for Breast cancer surveillance. JAMA 265:380–382CrossRefPubMed
9.
Zurück zum Zitat National Institute for Healthcare and Excellence Improving outcomes in breast cancer National Institute for Healthcare and Excellence Improving outcomes in breast cancer
11.
Zurück zum Zitat Cancer Care Ontario (2010) Cancer Care Ontario’s position. Guidelines for Breast Cancer Well Follow Up Care Cancer Care Ontario (2010) Cancer Care Ontario’s position. Guidelines for Breast Cancer Well Follow Up Care
12.
Zurück zum Zitat National Comprehensive Cancer Network (2023) NCCN Clinical Practice Guidelines in Oncology 2023 National Comprehensive Cancer Network (2023) NCCN Clinical Practice Guidelines in Oncology 2023
20.
Zurück zum Zitat European Comission (2019) Expert Panel on effective ways of investing in Health. EXPH) European Comission (2019) Expert Panel on effective ways of investing in Health. EXPH)
21.
Zurück zum Zitat World Health Organization Taking stock (2008) : Task shifting to tackle health worker shortages: World Health Organization Taking stock (2008) : Task shifting to tackle health worker shortages:
27.
Zurück zum Zitat Sisler J, Chaput G, Sussman J, Ozokwelu E (2016) Follow-up after treatment for Breast cancer: practical guide to survivorship care for family physicians. Can Fam Physician 62:805–811PubMedPubMedCentral Sisler J, Chaput G, Sussman J, Ozokwelu E (2016) Follow-up after treatment for Breast cancer: practical guide to survivorship care for family physicians. Can Fam Physician 62:805–811PubMedPubMedCentral
Metadaten
Titel
The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey
verfasst von
Ana-Alicia Beltran-Bless
Gail Larocque
Muriel Brackstone
Angel Arnaout
Jean-Michel Caudrelier
Denise Boone
Parvaneh Fallah
Terry Ng
Peter Cross
Nasser Alqahtani
John Hilton
Lisa Vandermeer
Gregory Pond
Mark Clemons
Publikationsdatum
09.01.2024
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2024
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-023-07232-3

Weitere Artikel der Ausgabe 3/2024

Breast Cancer Research and Treatment 3/2024 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.